

22 Sep 99

c) 1999 Derwent Publ Ltd. All rts. reserv.

0157153 DBA Accession No.: 93-15205 PATENT

Detection of point mutation using mismatch repair enzyme- by hybridization of DNA probe and binding of enzyme or DNA cleavage, for use in genetic disease diagnosis

PATENT ASSIGNEE: Univ. Maryland 1993

PATENT NUMBER: WO 9320233 PATENT DATE: 931014 WPI ACCESSION NO.: 93-336939 (9342)

PRIORITY APPLIC. NO.: US 859072 APPLIC. DATE: 920327

NATIONAL APPLIC. NO.: WO 93US2329 APPLIC. DATE: 930322

LANGUAGE: English

ABSTRACT: A new method for identifying a point mutation site in a nucleic acid comprises: obtaining single-stranded target nucleic acid; **hybridizing** oligonucleotides containing the site to the single-stranded nucleic acid, where the oligonucleotides may or may not be complementary at the site, to form a hybrid; exposing the hybrids to a mismatch repair enzyme which binds to mismatch bases to form an enzyme-nucleic acid complex, or that cleaves 1 strand containing a mismatched base pair; determining the presence of complexes or cleaved fragments; and identifying the base at the site. The enzyme may bind to or cleave at AG or TG base pairs, and the DNA may be **labeled** with a radiolabel, enzyme or dye, with cleaved fragments differentially **labeled**. A set of 2 primer pairs, of which 1 of each pair **hybridizes** the point mutation sequence and the other does not, is claimed. The method is useful in genetic disease diagnosis. (43pp)

DESCRIPTORS: point mutation det. method, DNA probe hybridization, mismatch repair enzyme binding or DNA cleavage, appl. genetic disease diagnosis (Vol.12, No.26)

SECTION: PHARMACEUTICALS-Clinical Genetic Techniques; GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid Technology (D7,A1)

0180691 DBA Accession N 95-08711 PATENT
Immobilized mismatch-binding protein for detection or purification of
mutations or polymorphisms - mutS immobilization and application
AUTHOR: Wagner Jr R E
PATENT ASSIGNEE: Gene-Check 1995
PATENT NUMBER: WO 9512689 PATENT DATE: 950511 WPI ACCESSION NO.:
95-185788 (9524)

PRIORITY APPLIC. NO.: US 147785 APPLIC. DATE: 931104
NATIONAL APPLIC. NO.: WO 94US12768 APPLIC. DATE: 941104

LANGUAGE: English

ABSTRACT: A new method for detecting a mutation from a non-mutated sequence of a target DNA in a sample involves: incubating a chromogenic-, chemiluminescent-, bioluminescent-, fluorescent- or biotin-labeled or radiolabeled polynucleotide or oligonucleotide from the sample with a mismatch-binding protein (I) immobilized on a solid surface (especially a nitrocellulose membrane) under conditions favoring binding of the mismatch-containing polynucleotides and immobilized (I); and detecting binding, where the presence of the labeled polynucleotides or oligonucleotides is indicative of a mutation in the sequence of the target DNA. (I) is the MutS protein or a derivative. Also new are: a method for detecting a mutation from a non-mutated sequence of mammalian ds target DNA; a method for removal from amplified DNA sample of minority sequences and sequence errors introduced during the amplification; a method for identifying a specific allele in a multi-allelic system in a sample of amplified DNA; a kit useful for the detection of a mutation from a non-mutated sequence of a target polynucleotide sequence in a sample; and immobilized (I). (39pp)

DESCRIPTORS: DNA polymorphism analysis, purification, point mutation detection, immobilized mutS mismatch -binding protein

immobilization (Vol.14, No.15)

SECTION: GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid Technology (A1)

0158109 DBA Accession No. 94-00660 PATENT
Genetic screening for nucleotide variation- point mutation detection
by hybridization, polymerase chain reaction and mismatch binding
protein affinity chromatography
PATENT ASSIGNEE: Massachusetts-Inst. Technol. 1993
PATENT NUMBER: WO 9322457 PATENT DATE: 931111 WPI ACCESSION NO.:
93-368815 (9346)

PRIORITY APPLIC. NO.: US 874192 APPLIC. DATE: 920424
NATIONAL APPLIC. NO.: WO 93US3777 APPLIC. DATE: 930422

LANGUAGE: English

ABSTRACT: A new method for genetic screening for nucleotide variation comprises: subjecting target and reference nucleic acids to conditions which allow them to anneal and produce a heteroduplex, each containing a mismatched nucleotide pair; treating the mixture with a mismatch binding protein, to bind this protein to the pair; and detecting the presence of the mismatch. The mismatch binding protein may be used as an adsorbent in affinity adsorption. The nucleic acid may first be amplified by the polymerase chain reaction, and the heteroduplex may also contain polymerase chain reaction tails. The heteroduplex may be labeled. Detection may also involve formation of an immune complex between an antibody and either the bound mismatch binding protein or the bound heteroduplex. The method has greatly increased sensitivity, and does not rely on restriction fragment length differences. The method also allows enrichment of heteroduplex fragments containing mismatches, even in samples containing excess homoduplex, allowing more sensitive detection of the mismatch. (88pp)

DESCRIPTORS: point mutation det. method, hybridization, polymerase chain reaction, mismatch binding protein affinity chromatography DNA amplification (Vol.13, No.2)

SECTION: GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid Technology (A1)

?ds

Set	Items	Description
S1	16	(MUTATION(3N)MISMATCH?) AND (HYBRIDIZ?(S)LABEL?)
S2	11	RD (unique items)
S3	0	(POINT()MUTATION()DETECTION)(S)(MUT S)
S4	3	(POINT()MUTATION()DETECTION)(S)(MISMATCH(3N)PROTEIN)

2/5/9 (Item 6 from File: 357)
DIALOG(R) File 357:Derwent Biotechnology Abs
(c) 1999 Derwent Publ Ltd. All rts. reserv.

0146445 DBA Accession No.: 93-04497 PATENT

Method for detection of mismatch mutation in DNA- rapid and simple
method for disease diagnosis or cancer diagnosis

PATENT ASSIGNEE: Upstate-Biotechnol. 1993

PATENT NUMBER: WO 9302216 PATENT DATE: 930204 WPI ACCESSION NO.:
93-058809 (9307)

PRIORITY APPLIC. NO.: US 732219 APPLIC. DATE: 910719

NATIONAL APPLIC. NO.: WO 92US6045 APPLIC. DATE: 920717

LANGUAGE: English

ABSTRACT: A new rapid, efficient and cheap method for detecting a mutation in a single-stranded polynucleotide (ssP) in a biological sample comprises: incubating the sample with an ssP **hybridization** partner (HP) comprising at least 1 ss base sequence complementary to the non-mutated sequence of the target polynucleotide, under conditions suitable for **hybridization** of the HP to any mutated or non-mutated sequences of the target polynucleotide to form a hybrid; contacting the hybrid with a mismatch-binding protein (MBP) (MutS protein, a derivative or a MutS-beta-galactosidase (BGal, EC-3.2.1.23) fusion protein (FP)); and detecting MBP bound to the hybrid (by addition of a **labeled** 1st binding partner, especially an antibody, capable of binding to the MBP or by addition of an unlabeled 1st binding partner and a **labeled** 2nd binding partner (antibody, MutL protein, MutL derivative, MutL-BGal-FP or enzyme) and detecting the 2nd). The HP is DNA or cDNA which is immobilized on a solid surface (nitrocellulose membrane). The target polynucleotide is DNA, and it is subjected to enzymic restriction prior to denaturation. A kit for the new method is also claimed. (76pp)

E.C. NUMBERS: 3.2.1.23

DESCRIPTORS: point mutation, deletion, addition, detection method, DNA probe hybridization, mismatch-binding protein, appl. disease, cancer diagnosis MutS MutL beta-galactosidase fusion protein enzyme antibody EC-3.2.1.23 tumor

SECTION: PHARMACEUTICALS-Clinical Genetic Techniques; GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid Technology (D7,A1)

0208116 DBA Accession N 97-03237 PATENT
Use of nucleic acid repair enzyme- diagnostic method for point mutation
detection by oligonucleotide DNA probe hybridization and cleavage
product detection

AUTHOR: Chirikjian J G; Collier B G
CORPORATE SOURCE: Gaithersburg, MD, USA.

PATENT ASSIGNEE: Trevigen 1996
PATENT NUMBER: WO 9640902 PATENT DATE: 961219 WPI ACCESSION NO.:
97-099933 (9709)

PRIORITY APPLIC. NO.: US 12950 APPLIC. DATE: 960306
NATIONAL APPLIC. NO.: WO 96US8694 APPLIC. DATE: 960607

LANGUAGE: English

ABSTRACT: A new method for detection of a point mutation in a target DNA involves: stringent **hybridization** of an ss oligonucleotide (ON) DNA probe to form a hybrid ds DNA, with a **mismatch** at the point **mutation** site; cleaving the probe at a predetermined temp. with a nucleic acid repair enzyme (e.g. mutY, T/G-mismatch-specific nicking enzyme, human or yeast all-type enzyme or *Escherichia coli* deoxyinosine-3'-endonuclease), optionally combined with a DNA-lyase or a DNA-AP-endonuclease, to dissociate ON fragments spontaneously at this temp.; repeating these steps; and detecting the ON fragments to indicate the presence of the point mutation. Cleavage may be effected by a glycosylase attached to the probe and an AP cleaving enzyme. A 2nd and/or 3rd probe may be **hybridized** to the target at an adjacent location, with separate cleavage components attached, and optionally with different lengths and fluorescence **labels**. A repair index for a mismatched or damaged ON probe may be determined using this method. The method may be used in accurate and efficient genetic disease diagnosis, without DNA amplification. (66pp)

DESCRIPTORS: point mutation det. method, oligonucleotide DNA probe
hybridization, mismatch DNA repair enzyme cleavage, fluorescence
label, appl. diagnostic mutY nicking enzyme human yeast all-type
enzyme *Escherichia coli* deoxyinosine-3'-endonuclease glycosylase
DNA-lyase DNA-AP-endonuclease DNA sequence protein sequence (Vol.16,
No.6)

SECTION: PHARMACEUTICALS-Clinical Genetic Techniques; GENETIC ENGINEERING
AND FERMENTATION-Nucleic Acid Technology (D7,A1)

23 Sept 99

>>SET HIGHLIGHT: use ON, OFF or 1-5 characters
6018 PNA
25257 POINT MUTATION
242463 HYBRIDIZ?
S1 8 PNA AND (POINT MUTATION)AND HYBRIDIZ?

?rd
...completed examining records
S2 6 RD (unique items)
?t s2/5/all

2/5/1 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

07446764 EMBASE No: 1998357080
PNA array technology in molecular diagnostics
Geiger A.; Lester A.; Kleiber J.; Orum H.
H. Orum, PNA Diagnostics A/S, Ronnegade 2, DK-2100 Copenhagen O Denmark
Nucleosides and Nucleotides (NUCLEOSIDES NUCLEOTIDES) (United States)
1998, 17/9-11 (1717-1724)

CODEN: NUNUD ISSN: 0732-8311
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 17

A comparative study using immobilised DNA and **PNA** oligomers demonstrates the suitability of **PNA** molecules as sequence specific capture probes in the detection of single point mutations in a DNA analyte and in the analysis of complex analyte mixtures.

DRUG DESCRIPTORS:

*peptide nucleic acid
oligomer; dna

MEDICAL DESCRIPTORS:

*molecular mimicry; *nucleic acid **hybridization**
dna probe; nucleotide sequence; immobilization; luminescence; **point mutation** ; conference paper

CAS REGISTRY NO.: 9007-49-2 (dna)

SECTION HEADINGS:

029 Clinical and Experimental Biochemistry

2/5/2 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

07130081 EMBASE No: 1998015073
Genetic analysis by peptide nucleic acid affinity MALDI-TOF mass spectrometry
Griffin T.J.; Tang W.; Smith L.M.
L.M. Smith, Department of Chemistry, University of Wisconsin-Madison,
1101 University Ave., Madison, WI 53706-1396 United States
AUTHOR EMAIL: smith@chem.wisc.edu
Nature Biotechnology (NAT. BIOTECHNOL.) (United States) 1997, 15/13
(1368-1372)

CODEN: NABIF ISSN: 1087-0156
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 24

The ability to analyze multiple polymorphic sites rapidly and accurately is crucial in all areas of genetic analysis. We have developed an approach for the detection of multiple point mutations, using allele-specific, mass-labeled, peptide nucleic acid (**PNA**) **hybridization** probes, and direct

analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The composite mass spectra produced contain peaks of distinct masses corresponding to each allele present, resulting in a mass spectral 'fingerprint' for each DNA sample. The **hybridization** characteristics of PNA :DNA duplexes were found to be highly dependent on both base content and sequence. Results from the analysis of four polymorphic sites contained in exon 4 of the human tyrosinase gene show that this approach is simple, rapid, and accurate with potential applications in many areas of genetic analysis.

DRUG DESCRIPTORS:

*peptide; *nucleic acid
dna; monophenol monooxygenase

MEDICAL DESCRIPTORS:

*genetic analysis; *nucleic acid **hybridization** ; *mass spectrometry
protein nucleic acid interaction; dna fingerprinting; **point mutation** ;
exon; genome; dna polymorphism; human; article; priority journal

CAS REGISTRY NO.: 9007-49-2 (dna); 9002-10-2 (monophenol monooxygenase)

SECTION HEADINGS:

022 Human Genetics

027 Biophysics, Bioengineering and Medical Instrumentation

2/5/3 (Item 3 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

06890886 EMBASE No: 1997175265

Detection of point mutation in the p53 gene using peptide nucleic acid biosensor

Wang J.; Rivas G.; Cai X.; Chicharro M.; Parrado C.; Dontha N.; Begleiter A.; Mowat M.; Palecek E.; Nielsen P.E.
J. Wang, Dept. of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003 United States
Analytica Chimica Acta (ANAL. CHIM. ACTA) (Netherlands) 1997, 344/1-2 (111-118)

CODEN: ACACA ISSN: 0003-2670

PUBLISHER ITEM IDENTIFIER: S0003267097000391

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 14

A 17-mer peptide nucleic acid (PNA) is used as the recognition layer of an electrochemical biosensor for detecting a specific mutation in the p53 gene. The performance of the PNA -derived biosensor is compared with that of its DNA counterpart. The significantly higher specificity of the PNA probe greatly improves the detection of a single point mutation, found in many types of cancer. Factors influencing the surface immobilization of the PNA probe, its **hybridization** to the p53 target sequence, and the chronopotentiometric detection step, are explored and optimized. This and similar developments hold promise for the diagnosis and management of cancer.

DRUG DESCRIPTORS:

*protein p53--endogenous compound--ec
peptide nucleic acid

MEDICAL DESCRIPTORS:

*electrochemistry; *genetic analysis
article; biosensor; cancer--diagnosis--di; cancer--etiology--et; human;
nonhuman; **point mutation** ; priority journal; technique

SECTION HEADINGS:

016 Cancer

022 Human Genetics
029 Clinical and Experimental Biochemistry

2/5/4 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06220694 EMBASE No: 1995257098
Enhanced PCR amplification of VNTR locus D1S80 using peptide nucleic acid (PNA)
Demers D.B.; Curry E.T.; Egholm M.; Sozer A.C.
Fairfax Identity Laboratories, Genetics and IVF Institute, 3025 Hamaker Ct, Ste 203 Fairfax, VA 22031 United States
Nucleic Acids Research (NUCLEIC ACIDS RES.) (United Kingdom) 1995, 23/15 (3050-3055)

CODEN: NARHA ISSN: 0305-1048
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Use of the polymerase chain reaction (PCR) to amplify variable numbers of tandem repeat (VNTR) loci has become widely used in genetic typing. Unfortunately, preferential amplification of small allelic products relative to large allelic products may result in incorrect or ambiguous typing in a heterozygous sample. The mechanism for preferential amplification has not been elucidated. Recently, **PNA** oligomers (peptide nucleic acids) have been used to detect single base mutations through PCR clamping. **PNA** is a DNA mimic that exhibits several unique **hybridization** characteristics. In this report we present a new application of **PNA** which exploits its unique properties to provide enhanced amplification. Rather than clamping the PCR, **PNA** is used to block the template making it unavailable for interstrand and intrastrand interactions while allowing polymerase to displace the **PNA** molecules and extend the primer to completion. Preferential amplification is reduced and overall efficiency is enhanced.

DRUG DESCRIPTORS:
oligomer; peptide nucleic acid

MEDICAL DESCRIPTORS:
*gene amplification; *polymerase chain reaction
allele; article; consensus sequence; controlled study; dna determination;
dna template; gene locus; gene technology; human; human cell; **point mutation** ; priority journal; tandem repeat

SECTION HEADINGS:
021 Developmental Biology and Teratology
022 Human Genetics
027 Biophysics, Bioengineering and Medical Instrumentation
029 Clinical and Experimental Biochemistry

2/5/5 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1999 INIST/CNRS. All rts. reserv.

13356195 PASCAL No.: 98-0083742
Mismatch-sensitive hybridization detection by peptide nucleic acids immobilized on a quartz crystal microbalance
WANG J; NIELSEN P E; JIANG M; CAI X; FERNANDES J R; GRANT D H; OZSOZ M; BEGLIETER A; MOWAT M
Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, New Mexico 88003, United States; Center for Biomolecular Recognition, IMBG, Department of Biochemistry B, The Panum Institute, Blegdamsvej 3c, 2200, Copenhagen, Denmark; Manitoba Institute of Cell Biology, Winnipeg, Manitoba R3E 0V9, Canada
Journal: Analytical chemistry : (Washington, DC), 1997, 69 (24)

5200-5202

ISSN: 0003-2700 CODEN: ANCHAM Availability: INIST-120B;
354000079772680390

No. of Refs.: 16 ref.

Document Type: P (Serial) ; A (Analytic)

Country of Publication: United States

Language: English

A quartz crystal microbalance DNA **hybridization** biosensor, based on thiol-derivatized peptide nucleic acid (PNA) probes, offers unusual *in situ* differentiation of single-base mismatches. A large excess of a single-base mismatch oligonucleotide has no effect on the frequency response of the target. Such remarkable distinction between perfect matches and mismatches is illustrated by the detection of a common mutation in the p53 gene. The greater specificity of the new mass-sensitive indicatorless **hybridization** device over those of analogous PNA-based carbon electrodes is attributed to the formation of a PNA monolayer and the use of a hydrophilic ethylene glycol linker. The improved specificity is coupled to very fast (3-5 min) **hybridization** in a low-ionic-strength medium.

English Descriptors: **Point mutation** ; Base mismatching; Investigation method; Molecular probe; Molecular hybrid; Peptides; Nucleic acid; Immobilization; Quartz microbalance; Biosensor; Tumor suppressor gene

French Descriptors: Mutation ponctuelle; Mesappariement base; Methode etude ; Sonde moleculaire; Hybride moleculaire; Peptide; Acide nucleique; Immobilisation; Microbalance quartz; Biодetecteur; Gene suppresseur tumeur; Gene p53

Classification Codes: 002A31C09B; 215

Copyright (c) 1998 INIST-CNRS. All rights reserved.

2/5/6 (Item 1 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 1999 Dialog Corporation. All rts. reserv.

09607880 98324861

Detection of the hereditary hemochromatosis gene mutation by real-time fluorescence polymerase chain reaction and peptide nucleic acid clamping.

Kyger EM; Krevolin MD; Powell MJ

Roche Diagnostics Boehringer-Mannheim Corporation, 4300 Hacienda Drive, Pleasanton, California, 94588-2722, USA. erich.kyger@mhc.boehringer-mannheim.com

Anal Biochem (UNITED STATES) Jul 1 1998, 260 (2) p142-8, ISSN 0003-2697 Journal Code: 4NK

Languages: ENGLISH

Document type: JOURNAL ARTICLE

JOURNAL ANNOUNCEMENT: 9810

Subfile: INDEX MEDICUS

Heredity hemochromatosis (HH), an iron overload disease, is the most common known inheritable disease. The most prevalent form of HH is believed to be the result of a single base-pair mutation. We describe a rapid homogeneous mutation analysis method that does not require post-polymerase chain reaction (PCR) manipulations. This method is a marriage of three emerging technologies: rapid cycling PCR thermal cyclers, peptide nucleic acid (PNA) probes, and a new double-stranded DNA-selective fluorescent dye, Sybr Green I. The LightCycler is a rapid thermal cycler that fluorometrically monitors real-time formation of amplicon with Sybr Green I. PNAs are DNA mimics that are more sensitive to mismatches than DNA probes, and will not serve as primers for DNA polymerases. PNA probes were designed to compete with PCR primers **hybridizing** to the HH mutation site. Fully complemented PNA probes at an 18:1 ratio over DNA primers with a mismatch result in suppression of amplicon formation. Conversely, PNA probes with a mismatch will not impair the binding of a complementary primer, culminating in amplicon formation. A LightCycler-based rapid genetic assay has been developed to distinguish HH patients from HH

carriers and normal individuals using PNA clamping technology. Copyright 1998 Academic Press.

Tags: Human

Descriptors: Hemochromatosis--Genetics--GE; *Oligodeoxyribonucleotides; * Point Mutation ; Base Composition; Base Sequence; DNA Primers; Fluorescent Dyes; Genetic Techniques; Heterozygote Detection; Homozygote; Oligonucleotide Probes; Peptides; Polymerase Chain Reaction--Methods--MT; Spectrometry, Fluorescence--Methods--MT

CAS Registry No.: 0 (DNA Primers); 0 (Fluorescent Dyes); 0 (Oligodeoxyribonucleotides); 0 (Oligonucleotide Probes); 0 (Peptides); 163795-75-3 (SYBR Green I)

3 July 2000

Set	Items	Description
S1	24019	(GREEN()) FLUORESCENT() PROTEIN) OR GFP
S2	4408752	S1 AND MISMATCH OR C/C
S3	46	S1 AND MISMATCH
S4	18	RD (unique items)
S5	2	S4 AND (C/C)
S6	171	S2 AND MISMATCH (2N) BINDING
S7	71	RD (unique items)
S8	70	S7 AND (C/C)
S9	0	S8 AND GFP(2N) LABE
S10	0	S8 AND GFP (2N) LABEL
S11	0	S8 AND GFP (4N) LABELED
S12	3	S8 AND MISMATCHED (2N) BASE?
S13	49	S8 NOT PY>=1999
S14	49	RD (unique items)
S15	19868	S1 AND (GREEN()) FLUORESCENT() PROTEIN)
S16	1	S1 AND (MISMATCH (2N) BINDING)
S17	532	AU="HAYASHIZAKI Y" OR AU="HAYASHIZAKI Y." OR AU="HAYASHIZA- KI YOSHIHIDE"
S18	161	RD (unique items)
S19	1	S18 AND (GREEN()) FLUORESCENT() PROTEIN OR GFP)
S20	114	S1 AND (PROTEIN()) LABEL?)
S21	35	RD (unique items)

11211658 BIOSIS NO.: 199799832803

Construction of a %green% fluorescent %protein% %labeled% gE mutant of HSV
for studies of intercellular viral spread.

AUTHOR: Chin M S(a); Margolis T P; Mendoza N T; Lavail J H

AUTHOR ADDRESS: (a)Dep. Anatomy, UCSF, San Francisco, CA 94143**USA
1997

JOURNAL: Society for Neuroscience Abstracts 23 (1-2):p2197 1997

CONFERENCE/MEETING: 27th Annual Meeting of the Society for Neuroscience
New Orleans, Louisiana, USA October 25-30, 1997

ISSN: 0190-5295

RECORD TYPE: Citation

LANGUAGE: English

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Infection; Nervous System (Neural Coordination); Sense Organs (Sensory Reception)

BIOSYSTEMATIC NAMES: Herpesviridae--Viruses

ORGANISMS: herpes simplex virus type-1 (Herpesviridae)

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): microorganisms; viruses

MISCELLANEOUS TERMS: Meeting Abstract; Meeting Poster; CELL-TO-CELL
VIRAL SPREAD; CORNEAL EPITHELIAL CELLS; %GREEN% %FLUORESCENT% %PROTEIN%
; INFECTION; INFECTIOUS BLINDNESS; NERVOUS SYSTEM; PATHOGEN; SENSORY
SYSTEM; TRIGEMINAL NERVE ENDINGS; VIRAL GLYCOPROTEIN E; VIRAL
REACTIVATION

CONCEPT CODES:

10064 Biochemical Studies-Proteins, Peptides and Amino Acids

10068 Biochemical Studies-Carbohydrates

20006 Sense Organs, Associated Structures and Functions-Pathology

20504 Nervous System-Physiology and Biochemistry

20506 Nervous System-Pathology

36006 Medical and Clinical Microbiology-Virology

00520 General Biology-Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals

BIOSYSTEMATIC CODES: